OTCMKTS:MAQAF Atlas Arteria (MAQAF) Stock Price, News & Analysis $2.66 0.00 (0.00%) As of 11/17/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Atlas Arteria Stock (OTCMKTS:MAQAF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atlas Arteria alerts:Sign Up Key Stats Today's Range$2.66▼$2.6650-Day Range$2.64▼$3.6852-Week Range$2.64▼$4.09VolumeN/AAverage Volume1,254 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield3.12%Price Target$5.03Consensus RatingHold Company Overview Atlas Arteria is an international toll-road owner and operator headquartered in Australia. The company invests in, manages and operates infrastructure assets under long-term concession agreements, generating revenue primarily through toll collection. Its activities include road operations, maintenance, customer services and the management of transportation infrastructure. Atlas Arteria’s principal assets are interests in APRR and AREA, major motorway networks in France serving commercial and passenger traffic across several regions. The company also owns and operates the Dulles Greenway, a privately operated toll road in Virginia that connects the Dulles area with the Washington, D.C., metropolitan region. The group was established as Macquarie Atlas Roads and adopted the Atlas Arteria name in 2018. It previously held an interest in the Chicago Skyway in the United States, which was divested in 2022. Atlas Arteria is listed on the Australian Securities Exchange and its securities also trade over the counter in the United States under the symbol MAQAF.AI Generated. May Contain Errors. Read More Atlas Arteria Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreMAQAF MarketRank™: 1.301445285615 of 5 starsAtlas Arteria scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingAtlas Arteria has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAtlas Arteria has a consensus price target of $5.03, representing about 89.1% upside from its current price of $2.66.Amount of Analyst CoverageAtlas Arteria has only been the subject of 1 research reports in the past 90 days.Read more about Atlas Arteria's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Atlas Arteria is -25.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atlas Arteria is -25.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverAtlas Arteria has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.Change versus previous monthShort interest in Atlas Arteria has recently increased by 1.57%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipAtlas Arteria is a leading dividend payer. It pays a dividend yield of 5.02%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthAtlas Arteria does not have a long track record of dividend growth.Read more about Atlas Arteria's dividend. News and Social MediaN/ANews SentimentN/A Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atlas Arteria insiders have not sold or bought any company stock.Percentage Held by Institutions24.06% of the stock of Atlas Arteria is held by institutions.Read more about Atlas Arteria's insider trading history. Receive MAQAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atlas Arteria and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAQAF Stock News HeadlinesAtlas Arteria (MAQAF) Receives a Hold from CitiOctober 26, 2026 | theglobeandmail.comPositive Report for Atlas Arteria (MAQAF) from JefferiesSeptember 6, 2026 | theglobeandmail.comThis Gold Pays Up To 15% (Government Can't Touch It)Larry Fink foresees $110 trillion in assets being tokenized, bigger than the entire US stock market. $1.6 billion has already moved into tokenized gold vaults. Meanwhile, your physical gold doesn't generate yield. And when governments need money? They confiscate it. In 1933 Roosevelt's Executive Order 6102 seized Americans' gold. Tokenized gold is backed by real bars in institutional vaults, but YOU hold the keys. So the only question that matters right now is whether you'll be holding the assets on the new financial rails when this completes... or whether you'll be the last person stuck on the old ones, watching your wealth get sliced in half because you didn't move when you had the chance. Lending it to traders can pay up to 8-15% annual yield, according to the presenter. | Decentralized Masters (Ad)Morgans Remains a Hold on Atlas Arteria (MAQAF)August 28, 2026 | theglobeandmail.comAtlas Arteria H1 2026 earnings: profit swings on one-offs, guidance heldAugust 26, 2026 | fool.com.auAnalysts Conflicted on These Industrial Goods Names: ALS (OtherCPBLF) and Atlas Arteria (OtherMAQAF)July 31, 2026 | theglobeandmail.comAtlas Arteria Q2 2026 earnings: Stable toll revenues, new debt facility boosts liquidityJuly 28, 2026 | msn.comEnd of the road: How IFM finally broke Atlas ArteriaJune 22, 2026 | afr.comSee More Headlines MAQAF Stock Analysis - Frequently Asked Questions How have MAQAF shares performed this year? Atlas Arteria's stock was trading at $2.84 at the start of the year. Since then, MAQAF stock has decreased by 6.3% and is now trading at $2.66. How do I buy shares of Atlas Arteria? Shares of MAQAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorIndustrials Industry Infrastructure Operations Sub-IndustryN/A Current SymbolOTCMKTS:MAQAF CIKN/A Webwww.atlasarteria.com Phone611800621694FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Atlas Arteria$5.03 High Price Target$5.31 Low Price Target$4.75 Potential Upside/Downside+89.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (OTCMKTS:MAQAF) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atlas Arteria Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Atlas Arteria With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.